目的:观察清肺口服液治疗小儿病毒性肺炎痰热闭肺证的临床疗效及安全性。方法:选取160例小儿病毒性肺炎痰热闭肺证患儿作为研究对象,随机分为观察组、对照组各80例,对照组患者采用常规治疗,观察组患者在常规治疗基础上给予清肺口服液治疗,观察比较两组患儿临床疗效及安全性。结果:经治疗,两组患者临床体征均明显改善,观察组患者改善情况明显优于对照组,差异具有统计学意义(P<0.05);观察组患者治疗优良率为90.00%,明显高于对照组的71.25%,差异具有统计学意义(P<0.05);治疗期间,两组患儿均未出现过敏、恶心、呕吐、肝肾功能障碍、贫血等不良反应。结论:在常规治疗基础上联合清肺口服液治疗小儿病毒性肺炎痰热闭肺证疗效明显,可有效改善患者症状体征,且安全性高,值得临床推广应用。 Objective: To observe the clinical efficacy and safety of Qingfei Oral Liquid in treating children with viral pneumonia and phlegm-heat and lung-closing syndrome. Methods: A total of 160 children with pneumonia of phlegm-heat and lung-closure syndrome were selected as study subjects and randomly divided into observation group and control group with 80 cases each. Patients in control group were treated by conventional therapy. Patients in observation group were given Qingfei lung Oral liquid treatment, observed and compared the clinical efficacy and safety of two groups of children. Results: After treatment, the clinical signs of the two groups were significantly improved. The improvement of the observation group was better than that of the control group, the difference was statistically significant (P <0.05). The excellent and good rate of the treatment group was 90.00%, significantly higher than the control group The difference was statistically significant (P <0.05). During the treatment, no adverse reactions such as allergy, nausea, vomiting, liver and kidney dysfunction and anemia occurred in both groups. Conclusion: The combination of Qingfei Oral Liquid and Qingfei Oral Liquid in the treatment of children with pneumoconiosis and phlegm-heat lungs syndrome has obvious curative effect. It can effectively improve the patients’ symptoms and signs, and is safe and worthy of clinical application.